Euroapi (EAPIF) Stock Price, News & Analysis

Company Overview

Euroapi is a standalone global active pharmaceutical ingredient (API) company formed in 2022 following its spin-off from the API division of a major multinational pharmaceutical group. The company focuses on the development, manufacturing and supply of a broad range of small-molecule APIs used in prescription drugs, over-the-counter products and vaccines. Its portfolio encompasses core areas such as semi-synthetic antibiotics (notably penicillins and cephalosporins), APIs for oncology, central nervous system disorders and cardiovascular therapies, as well as niche specialty ingredients.

Since its inception, Euroapi has pursued a growth strategy centered on innovation, capacity expansion and long-term partnerships with pharmaceutical customers. The group leverages both chemical synthesis and fermentation technologies to deliver complex molecules with high purity and consistent quality. In addition to standard API offerings, Euroapi provides custom development services, process optimization and contract manufacturing tailored to the specific needs of global drug developers and generic manufacturers.

Euroapi operates a network of manufacturing sites and research centers across Europe, North America and Asia. Its principal sites include facilities in France, Italy, Germany and the United Kingdom, complemented by operations in India and Canada to support capacity flexibility and regulatory diversification. This global footprint enables the company to meet stringent regulatory standards such as the European Medicines Agency (EMA) guidelines, the U.S. Food and Drug Administration (FDA) requirements and various international pharmacopoeias.

Led by an experienced executive team with deep expertise in API chemistry, regulatory affairs and supply-chain management, Euroapi is positioned to address ongoing industry challenges such as product scarcity, complex regulatory filings and sustainability targets. The company continues to invest in greener manufacturing processes and digital technologies to enhance efficiency and reduce its environmental footprint while maintaining a reliable supply of essential pharmaceutical ingredients to customers worldwide.

Key Stats

• Today's Range: C$3.20 to C$3.20
• 50-Day Range: C$3.09 to C$3.20
• 52-Week Range: C$2.46 to C$3.74
• Volume: N/A
• Average Volume: 1,933 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EAPIF Stock Analysis - Frequently Asked Questions

How have EAPIF shares performed this year?

Euroapi's stock was trading at C$3.00 on January 1st, 2025. Since then, EAPIF shares have increased by 6.7% and is now trading at C$3.20.

How do I buy shares of Euroapi?

Shares of EAPIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EAPIF
• CIK: N/A
• Web: www.euroapi.com
• Phone: 33 1 89 20 62 00
• Fax: N/A
• Employees: 3,329
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A